DPP4 and acute kidney injury: Case reports contrast with trial data: a recent network meta-analysis of RCTs indicates that SGLT2 inhibitors may have a lower AKI risk compared with dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1RAs) [12].